



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, July 2, 2020

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), is hereby reported the following:

OTHER RELEVANT INFORMATION

The Company announces that its partner in South Korea, Boryung Pharmaceutical, has presented the results of *in vitro* studies of plitidepsin (Aplidin[®]) in SARS-CoV-2.

According to the repeated evaluation of anti-viral activities against SARS-CoV-2 in Vero cell (monkey kidney cell) model by a reputable Korean research lab, which were requested by Boryung Pharmaceutical, plitidepsin has showed 2,400~2,800 times higher anti-viral activity than remdesivir (approved as the COVID-19 medication in Korea), and also 80 times higher activity than remdesivir in Calu-3 cell (human lung cell) model.

With these potent anti-viral data, and the expected reduction of the progression illness into Acute Respiratory Distress Syndrome (ARDS) in hospitalized COVID-19 pneumonia patients, along with a rapid recovery from the symptoms, Boryung Pharmaceutical has announced that they are preparing the clinical trials with plitidepsin in Korea and are aiming to begin in 3Q of 2020.

In April 2020, PharmaMar announced the start of the APLICOV-PC clinical trial with plitidepsin for the treatment of patients with COVID-19 in Spain.

In 2016, PharmaMar and Boryung Pharmaceutical signed a licensing agreement to commercialize the marine-derived anticancer drug, plitidepsin in South Korea. Under the terms of the agreement PharmaMar retains exclusive production rights and supplies the finished product to Boryung Pharmaceutical for commercial use.

Please find attached press release that will be distributed to the media today.

Boryung Pharmaceutical, PharmaMar's partner in South Korea, announces superior potent results for plitidepsin (Aplidin®) against SARS-CoV-2

- **Plitidepsin has showed 2,400~2,800 times higher anti-viral activity than remdesivir.**
- **Boryung Pharmaceutical to begin a clinical trial of plitidepsin in Korea in Q3 2020.**
- **In 2016, PharmaMar and Boryung Pharmaceutical signed a licensing agreement to commercialize plitidepsin in South Korea.**

Madrid, July 2nd, 2020.- PharmaMar (MSE:PHM) has announced today that its partner in South Korea, Boryung Pharmaceutical, has presented the results of *in vitro* studies of plitidepsin (Aplidin®) in SARS-CoV-2.

According to the repeated evaluation of anti-viral activities against SARS-CoV-2 in Vero cell (monkey kidney cell) model by a reputable Korean research lab, which were requested by Boryung Pharmaceutical, plitidepsin has showed 2,400~2,800 times higher anti-viral activity than remdesivir (approved as the COVID-19 medication in Korea), and also 80 times higher activity than remdesivir in Calu-3 cell (human lung cell) model.

With these potent anti-viral data, and the expected reduction of the progression illness into Acute Respiratory Distress Syndrome (ARDS) in hospitalized COVID-19 pneumonia patients, along with a rapid recovery from the symptoms, Boryung Pharmaceutical has announced that they are preparing the clinical trials with plitidepsin in Korea and are aiming to begin in 3Q of 2020.

In April 2020, PharmaMar announced the start of the APLICOV-PC clinical trial with plitidepsin for the treatment of patients with COVID-19 in Spain.

In 2016, PharmaMar and Boryung Pharmaceutical signed a licensing agreement to commercialize the marine-derived anticancer drug, plitidepsin in South Korea. Under the terms of the agreement PharmaMar retains exclusive production rights and supplies the finished product to Boryung Pharmaceutical for commercial use.



Plitidepsin (Aplidin®) is commercialized as a multiple myeloma medication in Australia, and its safety profile in human was confirmed with more than hundreds of subjects in several clinical trials in EU and USA. The drug product with finished dosage form is already available for the clinical trials.

"Being back to normal life is the most important for us at this moment in current COVID-19 crisis, and for this circumstances. Pharmaceutical companies shall seek various and innovative researches continuously for conquering COVID-19," said **Mr. Sam S. Lee**, CEO of Boryung Pharmaceutical. *"Boryung will accelerate to develop safe and efficient COVID-19 treatment through cooperation with partners."*

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Boryung Pharmaceutical Co., Ltd.,

Established in 1963, Boryung Pharmaceutical has been one of Korea`s leading pharmaceutical companies with sales revenue of KRW 524 billion, 1,700 employees and 580 sales representatives as of 2019. The company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea. The company has focused on the development and commercialization of new pharmaceutical products. Its main therapeutic categories are oncology, cardiovascular, anti-infective, respiratory and others. Especially Boryung is the strongest company in anti-cancer market in Korea. Additional information can be found at www.boryung.co.kr

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com